Jiang Juan,Yi Tingwu,Zhang Yu,Lan Jie,Lu You.Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(20):2039-2042.
Jiang Juan,Yi Tingwu,Zhang Yu,Lan Jie,Lu You.Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(20):2039-2042.DOI:
Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer
Objective To investigate the genetic status of epidermal growth factor receptor (EGFR) in cancer stem cells (CSCs) and non-cancer stem cells from non-small cell lung cancer (NSCLC). Methods Thirty-five NSCLC surgical fresh specimens were collected in our department and the Second Peoples’ Hospital of Sichuan Province from June 2010 to August 2011. CD133-positive cells and CD133-negative cells were sorted by flow cytometry after CD133 staining. Amplification refractory mutation system (ARMS) was employed to detect the presence of EGFR mutations in the 2 types of cells. The correlation of the EGFR mutations in different cells was analyzed. Results CD133-positive cells were detected in all collected specimens. The EGFR mutation rate was 28.6% in CD133-positive cells
which was higher in adenocarcinomas than in squamous cell carcinomas (P0.05). But there was no significant difference among different gender
age or smoking history (P0.05). The EGFR mutation rate was 42.9% in CD133-negative cells
which was higher in adenocarcinomas
and non- or slight-smokers (P0.05). There was no significant difference between different gender
or age (P0.05). There were 11 specimens out of 35 which had EGFR gene heterogeneity in both CD133-positive cells and CD133-negative cells (11/35
31.4%). The remaining 24 specimens had the same EGFR gene status in both CD133-positive cells and CD133-negative cells (18 cases exhibited EGFR wild type in both CD133-positive and -negative cells
and 6 cases displayed activating EGFR mutations regardless of CD133 expression). Conclusion There are EGFR genetic heterogeneity existing between CD133-positive cells and CD133-negative cells in NSCLC.
Relationship between plasma EGFR mutation and serum levels of tumor markers in non-small cell lung cancer
Integrative model combining deep learning, clinical and radiomic features enhances EGFR mutation prediction in non-small cell lung cancer
Preparation of doxorubicin-loaded polyphyllin H liposomes and synergistic anti-tumor activity against non-small cell lung cancer in vitro
Development of a postoperative recurrence prediction model for stage Ⅰ non-small cell lung cancer patients using multimodal data based on machine learning
Effect of chronic obstructive pulmonary disease on immunotherapy in patients with advanced non-small cell lung cancer
Related Author
肖何
王阁
王东
杨镇洲
杨宇馨
YANG Taotao
CHEN Wei
CHEN Cancan
Related Institution
Department of Radiology,First Affiliated Hospital, Army Medical University (Third Military Medical University)
Infervision Medical Technology Co., Ltd
Department of Radiology, Daping Hospital, Army Medical University
Department of Diagnostic Radiology, Eastern Theatre General Hospital
Department of Medical Service,No. Hospital of Joint Logistics Support Force